Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.

Rao L, Wu L, Liu Z, Tian R, Yu G, Zhou Z, Yang K, Xiong HG, Zhang A, Yu GT, Sun W, Xu H, Guo J, Li A, Chen H, Sun ZJ, Fu YX, Chen X. · 2020

Read Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. by Rao L, Wu L, Liu Z, Tian R, Yu G, Zhou Z, Yang K, Xiong HG, Zhang A, Yu GT, Sun W, Xu H, Guo J, Li A, Chen H, Sun ZJ, Fu YX, Chen X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7527506.txt.

Introduction

Rao and co-authors build hybrid cell membrane nanovesicles to fight cancer return. Cancer cells use CD47 as a do not eat me signal. That signal stops macrophages from eating them.

The vesicles carry a variant of SIRPα with stronger binding. They also carry signals that shift macrophages toward attack mode. Both tricks disable key defenses at once. In melanoma models, treatment cut local return and distant spread. Loaded with a STING agonist, vesicles also slowed triple negative breast cancer. The authors report the vesicles were safe and stable. They can also carry drugs and be edited.

Catalog record

CREATORRao L, Wu L, Liu Z, Tian R, Yu G, Zhou Z, Yang K, Xiong HG, Zhang A, Yu GT, Sun W, Xu H, Guo J, Li A, Chen H, Sun ZJ, Fu YX, Chen X.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE62 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7527506

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis By Lang Rao, Lei Wu, Zhida Liu, Rui Tian, Guocan Yu, Zijian Zhou, Kuikun Yang, Hong-Gang Xiong, Anli Zhang, Guang-Tao Yu, Wenjing Sun, Han Xu Published in: Nature Communications DOI: 10.1038/s41467-020-18626-y ABSTRACT Abstract Effectively activating macrophages against cancer is promising but challenging. In particular, cancer cells express CD47, a ‘don’t eat me’ signal that interacts with signal regulatory protein alpha (SIRPα) on macrophages to prevent phagocytosis. Also, cancer cells secrete stimulating factors, which polarize tumor-associated macrophages from an antitumor M1 phenotype to a tumorigenic M2 phenotype. Here, we report that hybrid cell membrane nanovesicles (known as hNVs) displaying SIRPα variants with significantly increased affinity to CD47 and containing M2-to-M1 repolarization signals can disable both mechanisms. The hNVs block CD47-SIRPα signaling axis while promoting M2-to-M1 repolarization within tumor microenvironment, significantly preventing both local recurrence and distant metastasis in malignant melanoma models. Furthermore, by loading a stimulator of interferon genes (STING) agonist, hNVs lead to potent tumor inhibition in a poorly immunogenic triple negative breast cancer model. hNVs are safe, stable, drug loadable, and suitable for genetic editing. These properties, combined with the capabilities inherited from source cells, make hNVs an attractive immunotherapy. Subject terms: Cancer immunotherapy, Nanotechnology in cancer INTRODUCTION Cancer recurrence and metastasis account for over 90% of cancer-induced mortality1,2. Despite continuing improvements in surgical methods and other treatment modalities, residual microtumors and circulating tumor cells (CTCs) remain to be major stumbling blocks in cancer therapy2,3. Much effort have been invested in developing new and effective therapeutic approaches towards battling cancer recurrence and metastasis4–6. Among these approaches, immunotherapy for the purpose of activating the body’s immune system against cancer has gained significant attention and stand ready to join traditional treatment modalities as an adjuvant treatment7,8. The innate immune system is a first line of defense in the body and macrophages play an indispensable role in its operation9. Effective activation of macrophages to ‘eat’ cancer cells holds great potential for cancer immunotherapy10. Unfortunately, cancer cells express CD47, which protects them from macrophage phagocytosis by sending a ‘don’t eat me’ signal via the signal regulatory protein alpha (SIRPα) receptor11,12. Disrupting the CD47-SIRPα signaling axis has been explored as a potential immunotherapeutic strategy13,14. Our recent studies have suggested that CD47 blockade not only promotes the phagocytosis of cancer cells by macrophages but also boosts the antitumor T cell immunity15, suggesting further potential in this emerging immunotherapeutic target. More than ten CD47 antagonists are currently being tested in clinical trials, while the objective response rate and clinical benefit rate of which require further improvements16. Also to note, systemic administration of CD47 antagonists can induce severe side effects including anemia and thrombocytopenia8,16. Efforts to address these concerns are critical in making anti-CD47 immunotherapy clinically feasible. One mechanism that may be compromising the efficacy of CD47-blocking therapy is the immunosuppressive tumor microenvironment (TME) which is rich in signals that polarize tumor-associated macrophages (TAMs) towards a pro-tumorigenic M2 phenotype17. M2-type macrophages can recruit regulatory T cells (Tregs) and secret anti-inflammatory cytokines which counteract the activation of antitumor T cell immunity by CD47 blocking agents8,18. In this context, repolarization of TAMs from a pro-tumorigenic M2 phenotype to an antitumor M1 phenotype may restore efficacy to antitumor immunity of CD47 antagonists. In addition, the side effects and limited effectiveness may be caused by nonspecific binding of these CD47 blockades to normal tissues when systemically infused5,16. Thus, it would be ideal for CD47 blocking cancer immunotherapy to focus on the tumor site and avoid interactions in the immune milieu of the other sites. Extracellular vesicles (EVs), including but not limited to exosomes and microvesicles, are lipid vesicles secreted by cells19. Recent evidence has suggested that EVs are involved in numerous physiological and pathological processes, and potentially have translational utility in immunotherapeutic agents for cancer treatment20–22. Due to their desirable safety characteristics and stability, using EVs as drug delivery vehicles attracted much attention19,23,24. In terms of production, however, the quantity of EVs secreted by cells is insufficient for use in drug delivery19. As a result, cellular nanovesicles (NVs), which can be produced by serial sonication and extrusion of cell membranes, have been utilized as alternatives to EVs25–27. More importantly, the NVs contain lipids and proteins of source cells and inherit multiple unique capabilities from the source cells28. For example, platelet-derived NVs (P-NVs) can interact with CTCs in the blood and bind to damaged vasculature and tissues29–32; M1 macrophage-derived NVs (M1-NVs) can repolarize TAMs to an M1-like phenotype33,34. Moreover, we have recently reported a facile method for fusing NVs derived from two different types of cells, resulting in hybrid NVs containing characteristics from both source cells30. In this study, we report a hybrid NVs (known as hNVs) that can amplify macrophage responses against cancer recurrence and metastasis after surgery. The hNVs consist of P-NVs, M1-NVs, and cancer cell-derived NVs overexpressing high-affinity SIRPα variants (SαV-C-NVs) (Fig. 1a). We show that the hNVs, which inherit the capabilities from source cells, can efficiently accumulate in surgical wound sites, interact with CTCs in the blood, repolarize TAMs towards M1 phenotype, and block the CD47-SIRPα interaction (Fig. 1b), thus accentuating macrophage phagocytosis of cancer cells, as well as potentiating antitumor T cell immunity, while reducing side effects induced by systemic infusion. In malignant melanoma models, we demonstrate that i.v. infusion of hNVs significantly prolong overall mouse survival by controlling both local recurrence and distant metastasis after surgery. Furthermore, by using a poorly immunogenic triple negative breast cancer model, we show that hNVs enhance the cytosolic delivery of a stimulator of interferon genes (STING) agonist and in turn, the agonist reprograms ‘cold’ tumors towards immunogenic states and improves the therapeutic efficacy of hNVs in a feedback manner. We anticipate the hNVs, which use only biocompatible cell membrane components, will provide additional insights on the development of safe and effective cancer immunotherapy strategy. [Figure: Schematic and characterization of hNVs.a Schematic showing the hNVs consist of engineered SαV-C-NVs, M1-NVs, and P-NVs. b Schematic showing the hNVs efficiently interact with CTCs in the blood, accumulate in the post-surgical tumor bed, repolarize TAMs towards M1 phenotype, and block the CD47-SIRPα ‘don’t eat me’ pathway, thus promoting macrophage phagocytosis of cancer cells, as well as boosting antitumor Tcell immunity. c, d Immunofluorescence imaging c and flow cytometry analysis d of SαV expression on original and engineered B16F10 cells. Scale bar, 10 µm. e Relative mRNA expression of Cd86, Tnf, Il6, and Inos in M0 cells, M1 cells, M0-NVs and M1-NVs. f Hydrodynamic size and zeta potential of P-NVs, M1-NVs, SαV-C-NVs, and hNVs measured by DLS. g TEM images of hNVs. Scale bar, 100 nm and 50 nm in the left and right panel, respectively. The samples were negatively stained with uranyl acetate. h Immunofluorescence images of hNVs. Scale bar, 10 µm. i Western blot analysis of specific protein CD61, CD14, and Melan-A in the samples of P-NVs, M1-NVs, SαV-C-NVs, and hNVs. All data are presented as mean ± S.D. (n = 3). Statistical significance was calculated via unpaired two-tailed t test. **P < 0.01; ***P < 0.001.] RESULTS Preparation and characterization of hNVs Briefly, the preparation of hNVs includes two steps: 1) obtaining engineered cells and the derived NVs, and

Read the complete text